Page 28 - Ace2 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

As new variants of SARS-CoV-2 continue to emerge, fueling the continued spread of the COVID-19 pandemic, a new study offers encouragement.

SARS-CoV-2 spike S1 subunit induces hypercoagulability The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), is characterized by a range of clinical presentations. The vascular complications of the condition include a range of various coagulopathies that cause bleeding and thrombocytopenia or a hypercoagulable state. A new preprint research paper posted to the medRxiv* server describes the role of a fibrinogen-related protein in inducing these clinical features of COVID-19. Cytokine dysregulation Earlier research has sho...

Researchers from Germany and the US investigated the efficacy of neutralizing antibodies against newer variants using serum and saliva samples obtained from groups of infected, vaccinated (with Pfizer BNT-162b2), and uninfected individuals. The researchers started this study to uncover vaccine-induced immune response and show the efficiency of antibody binding and neutralization in SARS-CoV-2 variants.

SARS-CoV-2 can infect blood monocytes and trigger inflammation, finds study Researchers found about 10% of blood monocytes in coronavirus disease 2019 (COVID-19) patients are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These monocytes then die, leading to the release of cytokines – a feature associated with severe and critical COVID-19. In some COVID-19 patients, SARS-CoV-2 infection can lead to acute respiratory distress and multi-organ failure and death. Severe disease has been associated with increased pro-inflammatory cytokines and C-reactive protein. Mye...

A team of scientists from the USA recently developed a recombinant “Angiotensin converting enzyme 2 (ACE2) Triple Decoy” that can trap SARS-CoV-2 and prevent its propagation inside the host cell.